Alembic Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals announced audited results for Q4 and FY25 along with key board decisions. Consolidated revenue from operations grew 7.1% YoY to Rs. 6,672.08 crores, while Q4 revenue rose 16.7% to Rs. 1,769.64 crores. However, consolidated profit after tax fell about 5% to Rs. 583.42 crores and standalone PAT dropped sharply by 24.5% to Rs. 503.12 crores, reflecting margin pressure. An exceptional gain of Rs. 12.87 crores from a settled insurance claim related to the October 2023 Sikkim floods was recognized. The Board recommended a dividend of Rs. 11 per share (550%), unchanged from last year. M/s. KKC & Associates LLP has been appointed as the new statutory auditor for five years, replacing M/s. K.C. Mehta & Co. LLP upon completion of their term, and the outgoing auditor issued an unmodified opinion on FY25 results.
A routine auditor rotation at end of term, an unchanged dividend, and modest revenue growth should be neutral for shareholders. The notable concern is the decline in profitability despite revenue growth, particularly on a standalone basis where PAT dropped nearly a quarter, which may weigh on near-term sentiment.